AI-Powered Oncology Prior Authorization Services
Outsourced oncology PA team handling chemotherapy, immunotherapy, radiation, biomarker testing, and high-cost biologics inside Epic, Athena, eClinicalWorks, and AdvancedMD. AAPC-credentialed specialists paired with AI agents that cite NCCN evidence on every submission. 4-hour standard turnaround. Live in 5 to 10 days.
How we get oncology prior auths approved in hours, not days.
Walk through our oncology PA workflow, from intake to approval, for 800+ providers.
Tell us your practice. We’ll project your savings in 24 hours.
Single specialty or multi-site? Front desk or full clinical? Send us your situation. We map the right PA team mix.
What Is Oncology Prior Authorization?
Picture Monday morning at an oncology practice. Twenty-three pending prior authorizations on the queue. Two infusion appointments waiting on payer approval. A peer-to-peer review at 11 a.m. that no one prepped NCCN citations for. That’s the day oncology PA tries to eat.
Oncology prior authorization is the payer’s gate before non-emergent oncology care. Chemotherapy infusions, immunotherapy (Keytruda, Opdivo, Tecentriq), antibody-drug conjugates, targeted therapy, monoclonal antibodies, radiation therapy (IMRT, SBRT, proton beam), biomarker and genomic testing (HER2, EGFR, KRAS, BRCA, MSI), and high-cost cancer biologics. Each payer has its own medical necessity policy. Each procedure has its own documentation set.
Staffingly’s AI-powered oncology PA service handles the full workflow. AI agents read the chart, pull the pathology report, biomarker results, and treatment plan, then match them to NCCN Category 1 evidence and the payer’s policy. AAPC-credentialed PA specialists review, sign off, and submit through CoverMyMeds, Availity, AIM, eviCore, and direct payer portals. Standard turnaround is 4 hours. Expedited oncology PAs go out within 60 minutes.
Most oncology practices pair PA with our oncology eligibility verification, oncology medical billing, and oncology credentialing to keep first-pass approval rates high and AR days low.
What Oncology Groups Need to Know About PA in 2026
CMS-0057-F took effect January 1, 2026 for impacted payers: Medicare Advantage, state Medicaid FFS and Managed Care, CHIP FFS and Managed Care, and FFE Qualified Health Plan issuers. Those plans now owe a PA decision within 7 calendar days standard and 72 hours expedited, with a specific denial reason every time. The first public reporting deadline for PA approval and denial metrics was March 31, 2026. Commercial PPO and HMO plans outside this list are not directly bound by the rule, though most are aligning voluntarily.
Oncologists average 39 PA requests per week per the 2024 AMA survey, and 31 percent say PAs are often or always denied. When practices appeal with NCCN evidence, 81.7 percent of denials are overturned fully or partially. That’s revenue and treatment delay sitting in a workflow most practices under-resource.
Hiring an in-house oncology PA coordinator costs $55K to $84K fully loaded. Staffingly’s outsourced oncology PA service runs $399 per role per week at single tier, $349 at team, $299 at department or enterprise. Live in 5 to 10 days. 2-week risk-free pilot.
Why Oncology PA Eats Days Most Groups Don’t Have
Oncology PA isn’t one workflow. It’s seven. Chemotherapy has one criteria set. Immunotherapy has another. Radiation therapy (IMRT, SBRT, proton beam) pulls in tumor type, prior failed therapy, and ACR appropriateness criteria. CAR-T and bispecific antibodies need genetic mutation status, performance status, and prior line documentation. Biomarker testing (HER2, EGFR, KRAS, BRCA, MSI) needs the diagnostic CPT plus pathology report. Each payer rewrites these annually.
Layer on the peer-to-peer review. The 2024 AMA survey found only 15 percent of physicians say the peer is actually qualified to make the call. That’s an hour of a medical oncologist’s day spent explaining NCCN evidence to someone outside the specialty.
That’s why mid-size and enterprise oncology groups outsource. Not to cut a coordinator. To stop losing 13 hours of physician time per week to a workflow that doesn’t need a physician.
How Staffingly’s Oncology PA Is Built Different
AI + AAPC-credentialed PA specialists, working inside your EMR. Not portal data entry. Not call-center scripts. A clinical-grade PA team that knows oncology.
AI + Specialist Pairs
AWS Bedrock clinical reasoning agent reads the path report and drafts the medical necessity narrative with NCCN citations. An AAPC-credentialed PA specialist reviews, refines, and submits. AI handles 80 percent of keystrokes.
NCCN-Anchored
Day-one productive on pathology reports, biomarker results (HER2, EGFR, KRAS, BRCA, MSI-H, PD-L1), staging documentation, and prior line records. Every appeal cites NCCN Category 1 or 2A evidence.
EMR-Native
Works inside Epic, Athena, eClinicalWorks, AdvancedMD, Cerner, NextGen, and Kareo. No screen-share. No data re-entry. Direct EMR access via encrypted VPN with full audit trail.
HIPAA + SOC 2 + ISO 27001
BAA signed before day one. SOC 2 Type II audited. ISO 27001 and HITRUST CSF aligned controls. Read our HIPAA security posture.
Specialty Pharmacy Hub
Integrated with AssistRx (iAssist) and major specialty pharmacy hubs for biologics, oral oncolytics, and infused therapy access. We coordinate hub enrollment alongside PA submission.
Peer-to-Peer Prep
We brief your oncologist before the peer-to-peer call. Pathology, biomarker status, prior line documentation, NCCN guideline citations. Most of our peer-to-peers turn into approvals.
Denial Recovery
Every denial gets analyzed by our AI appeal agent. 81.7 percent of appealed denials overturn per the 2024 AMA PA survey. We work that statistic to your favor with structured letters, evidence packs, and IRO escalation when needed.
2-Week Risk-Free Pilot
Scope one workflow (typically immunotherapy or chemo). 14 days. If the throughput, accuracy, and turnaround don’t hold, you walk away. Most pilots convert to full rollout.
Oncology Procedures and Drugs We Handle Prior Auth For
Common oncology CPT and HCPCS codes that trigger PA across commercial, Medicare Advantage, and Medicaid Managed Care. Our specialists know the NCCN-anchored documentation for each.
| CPT / HCPCS | Procedure | Typical PA Trigger | Common Documentation |
|---|---|---|---|
| 96413 | Chemotherapy IV infusion, up to 1 hour | All payers | Pathology, treatment plan, prior line documentation, NCCN evidence |
| 96367 | Each additional sequential infusion, up to 1 hour | Bundled with 96413 | Same encounter documentation |
| 96365 | Therapeutic IV infusion (non-chemo) | Most plans | For supportive care drugs and antibodies |
| J9035 | Bevacizumab (Avastin), 10 mg | All payers, NCCN-required | Tumor type, biomarker if applicable, line of therapy |
| J9271 | Pembrolizumab (Keytruda), 1 mg | All payers, biomarker-tied | PD-L1 status, MSI/TMB testing, tumor type |
| J9173 | Durvalumab (Imfinzi), 10 mg | All payers | NSCLC stage, prior chemoradiation documentation |
| J9355 | Trastuzumab (Herceptin), 10 mg | All payers, HER2-required | HER2 IHC 3+ or FISH+ documentation |
| 77386 | IMRT delivery, complex | All payers | Tumor type, ACR appropriateness, treatment plan |
| 77373 | SBRT delivery, per fraction | All payers | Tumor location, lesion count, SRS criteria |
| 77520 | Proton beam delivery, simple | All payers | Tumor type, prior radiation history, age (pediatric strong) |
| 81445 | Targeted genomic panel, 5-50 genes | Most payers | Tumor type, NCCN-supported indication |
| Q5112 | Trastuzumab biosimilar (Ogivri) | All payers | Same documentation as J9355 |
Coverage rules change by payer and by plan. Our payer policy library is refreshed monthly across commercial, Medicare Advantage, Medicaid Managed Care, and Tricare.
How a Oncology PA Moves Through Staffingly
Intake from EMR
AI agent pulls the order, clinical note, prior imaging, and demographic data from your EMR within minutes of the order being placed. No staff trigger needed.
AI medical necessity draft
AWS Bedrock matches clinical data to the patient’s payer policy and drafts the medical necessity narrative with citations specific to oncology, in the right format for each payer.
Specialist review and submit
An AAPC-credentialed oncology PA specialist reviews the AI draft, fixes anything the agent missed, and submits via CoverMyMeds, Availity, Carelon, eviCore, or the payer portal.
Status monitoring
We poll for status every 4 hours. CMS-0057-F windows kick in for MA, Medicaid MC, and CHIP: 72 hours expedited, 7 days standard. When the decision lands, we route it back into your EMR.
Peer-to-peer prep
If the payer requires P2P, we brief your provider with chart highlights, prior therapy timeline, and specialty-society guideline citations 30 minutes before the call. Most P2Ps convert to approval.
Appeals if denied
Denials flow to our appeals agent. Structured letters, evidence packs, IRO escalation if needed. Per the 2024 AMA PA survey, 81.7 percent of appealed denials overturn fully or partially.
A Oncology Denial Overturned With AI-Drafted Appeal
Representative Scenario · Pembrolizumab (Keytruda) · UHC MA Plan
A 5-oncologist practice in Florida (FL) sent us a 3-day-old denial on J9271 pembrolizumab for a 71-year-old patient with metastatic NSCLC, PD-L1 TPS 60%, no prior systemic therapy. The UHC MA reviewer denied citing “insufficient documentation of biomarker testing prior to immunotherapy.”
Our PA specialist pulled the chart, attached the PD-L1 IHC report showing TPS 60% (above the NCCN-required 50% threshold for first-line monotherapy), staging CT and PET findings, and packaged the NCCN NSCLC Guidelines v5.2026 as the appeal anchor citing Category 1 evidence for pembrolizumab monotherapy. We briefed the oncologist 30 minutes before the P2P call with chart highlights and 3 NCCN citations queued by section.
Outcome: Approval issued during the P2P call. Infusion scheduled 6 days later. Total Staffingly time from intake to approved: 7 hours. The case sits inside the 81.7 percent appeal overturn band the 2024 AMA PA survey documented across specialties.
Scenario composited from anonymized client workflows. No PHI shown. Outcomes vary by chart strength, payer, and reviewer.
How AI and Automation Make Oncology PA Faster and More Accurate
80 percent automation, 20 percent clinical judgment
Our oncology PA stack pairs AWS Bedrock for clinical reasoning with n8n for payer workflow orchestration. The Bedrock agent reads pathology reports, biomarker results, staging documents, and oncologist notes, then matches them to NCCN Category 1 evidence and the payer’s medical necessity policy. Google Vertex AI classifies supporting documents (path reports, imaging, prior auth letters) so nothing gets missed.
InsuVerifAI, our proprietary EV+PA SaaS, handles eligibility checks in parallel so the team always has live coverage data before submitting. For ePA-enabled cancer drugs, we route through CoverMyMeds and Surescripts. AssistRx (iAssist) handles specialty pharmacy hub enrollment for biologics. Claude 4.5 Haiku powers our voice agent for peer-to-peer scheduling.
The result: AI handles roughly 80 percent of the keystrokes. The AAPC-credentialed PA specialist owns the 20 percent that needs clinical judgment, NCCN interpretation, and peer-to-peer prep. We never claim fully automated oncology PA, because cancer treatment decisions need a human. The combination gets us to a 4-hour standard turnaround and above-industry first-pass approval.
One Flat Weekly Rate. No Surprises.
Dedicated prior authorization specialists at a fixed weekly cost. 45 hours per week, fully managed. No contracts, no minimums, no hidden fees.
One prior authorization specialist, single-location practice
5+ specialists, mid-size practice or health system region
10+ specialists, multi-location health system or PE-backed group
All plans include dedicated prior authorization specialists, payer portal access, EMR integration, and a 2-Week Risk-Free Pilot with a signed BAA. No long-term contract required.
Remote Oncology PA, Delivered Across the U.S. and Canada
Our PA specialists work from secured Staffingly facilities in India, Pakistan, and Bangladesh. Every specialist is overseas-licensed and educated in healthcare administration, AAPC-credentialed, and HIPAA-trained before day one. Oncology groups in Texas (TX), Florida (FL), California (CA), New York (NY), New Jersey (NJ), Illinois (IL), Pennsylvania, Ohio (OH), Georgia (GA), North Carolina (NC), Arizona (AZ), and Michigan (MI) run their oncology PA queue with us.
Pair Oncology PA With:
Real-time benefit checks before every infusion, radiation, or biologic.
CPT and ICD-10 coding accuracy across chemo, radiation, and biologics.
Payer enrollment and revalidation for medical and radiation oncologists.
The AI stack powering our oncology PA and EV workflows.
Related Prior Authorization Services:
Common Questions About Oncology Prior Authorization
What is oncology prior authorization and when is it required?
How does AI-powered oncology prior authorization work?
How long does oncology prior authorization take with Staffingly?
Why does my immunotherapy keep getting denied when PD-L1 status is documented in the chart (AI-Powered Oncology Prior Authorization Services)?
PET-CT for restaging keeps getting denied as ‘surveillance.’ What documentation gets restaging approved (AI-Powered Oncology Prior Authorization Services)?
Proton beam therapy is denied 34 percent of the time on first pass per published data. What flips it on appeal (AI-Powered Oncology Prior Authorization Services)?
Are oncology PAs really at 92 percent care delay rate, and what can I actually do about it (AI-Powered Oncology Prior Authorization Services)?
How fast can an oncology practice go live?
Who handles urgent immunotherapy prior authorizations for Aetna?
How do I outsource prior authorization for my oncology practice?
Can AI submit an oncology prior authorization without a human?
Talk to a real human about your Oncology Prior Authorization
30-minute strategy call. We map your oncology PA volume, payer mix, and EMR setup. No slide deck, just a working plan.
Dan Nandan is the President and CEO of Staffingly, Inc. With 25+ years in IT consulting and healthcare BPO operations, he was one of the earliest U.S. operators to set up an RPO/BPO delivery network in India over 20 years ago. Today his work centers on AI-driven healthcare workflows and helping oncology practices and health systems cut administrative costs without compromising patient care.
Connect on LinkedIn
Bincy Shiiju Kuriakose is a Clinical Content Reviewer at Staffingly and a U.S. Licensed Registered Nurse (MSN, RN). NCLEX-RN certified with expertise in hospital nursing, telehealth, and nursing education. Reviews every service page for clinical accuracy, HIPAA compliance, and evidence-based best practices.
Connect on LinkedInWhere Our Oncology PA Data Comes From
Every stat, threshold, and regulatory window on this page traces back to a primary source. We do not invent numbers.
- CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F). effective dates and decision windows
- 2024 AMA Prior Authorization Physician Survey. 39 PAs per week, denial rates, burnout data
- AMA Prior Authorization Research and Reports. 81.7 percent appeal overturn rate
- NCCN Clinical Practice Guidelines in Oncology. Category 1 evidence anchor for appeals
- CMS Article A53049. Approved Drugs and Biologicals (Chemotherapeutic Agents). Medicare coverage and edit rules
- FDA Oncology Approvals Database. approval status and label indications
- ASCO Practice and Quality Resources. oncology value-based care benchmarks
- KFF Medicare Advantage Prior Authorization Data. MA plan PA volume and denial trends
- MGMA Medical Group Practice Benchmarks. PA staffing and cost benchmarks
- HFMA Revenue Cycle Resources. AR days, denial rates, and PA workflow benchmarks
